Hematologic Malignancies – serie

This book summarizes current knowledge of the biology and molecular pathogenesis of aggressive lymphomas and reviews the state of the art in diagnostic and therapeutic strategies. The aim is both to provide the reader with a sound understanding of the very significant progress that has been achieved in the understanding and management of these malignancies over recent years and to facilitate appropriate choice of the therapeutic strategy in individual cases. The assessment of different prognostic parameters are clearly presented in order to permits effective risk stratification that impacts on treatment choice. Recent insights into lymphomagenesis are exemplified and may assist in identifying emerging therapeutic targets. The comprehensive and up-to-date nature of the book will make it an ideal reference for all physicians and researchers interested in lymphoma, including clinicians from various medical specialties, biologists, pathologists, radiologists and nuclear medicine specialist, as well as students.

The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies.

This book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. General treatment concepts are clearly described, and it is explained how choice of treatment for CLL depends on stage, age, and performance status as well as specific genetic aberrations.

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myelomaand Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management.

This book, now in its third edition, examines the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the appropriate management in special clinical circumstances, including in the elderly, pregnant women, and those with nodular lymphocyte-predominant disease (NLPHL). Careful attention is devoted to the emerging individually tailored treatment strategies, including checkpoint inhibition, that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The new edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by key opinion leaders to reflect recent progressin the field. It will be of great value to hematologists, oncologists, and all others with an interest in Hodgkin lymphoma.

This book, now in its third edition, examines the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the appropriate management in special clinical circumstances, including in the elderly, pregnant women, and those with nodular lymphocyte-predominant disease (NLPHL).

The new edition of this well-received book provides a timely update of current knowledge on the biology, disease classification, and treatment of the acute leukemias – acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

The new edition of this well-received book provides a timely update of current knowledge on the biology, disease classification, and treatment of the acute leukemias – acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).

The coverage encompasses follicular lymphoma, MALT, nodal marginal zone lymphoma, splenic marginal zone lymphoma, Waldenström’s macroglobulinemia, hairy cell leukemia, chronic lymphocytic leukemia, mycosis fungoides, large granular lymphocytic leukemia, and also mantle cell lymphoma.

The coverage encompasses follicular lymphoma, MALT, nodal marginal zone lymphoma, splenic marginal zone lymphoma, Waldenström’s macroglobulinemia, hairy cell leukemia, chronic lymphocytic leukemia, mycosis fungoides, large granular lymphocytic leukemia, and also mantle cell lymphoma.

This book provides a thorough update on the management of infections in patients with hematologic malignancies, focusing particularly on prevention, diagnosis, and treatment.

This book provides a thorough update on the management of infections in patients with hematologic malignancies, focusing particularly on prevention, diagnosis, and treatment.

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health.

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health.

This book, written by a team of leading experts, provides a comprehensive overview of acute myeloid leukemia (AML), the most frequent acute leukemia in adults.

This book, written by a team of leading experts, provides a comprehensive overview of acute myeloid leukemia (AML), the most frequent acute leukemia in adults.

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find Multiple Myelomaand Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management.

This book examines in detail the current treatment options for first-line, relapsed, and refractory Hodgkin lymphoma and the management appropriate in special clinical circumstances, including in the elderly, pregnant women, and those with lymphocyte-predominant disease. Careful attention is devoted to the emerging individually tailored treatment strategies that are especially appealing given their potential to reduce early and late treatment side effects in this generally young patient population. In addition, clear guidance is provided on the management of Hodgkin survivors. Other topics addressed include epidemiology, pathogenesis, the role of the microenvironment, initial clinical evaluation, imaging diagnosis, use of staging systems, and prognostic factors. The second edition of Hodgkin Lymphoma: A Comprehensive Overview has been revised and updated by the key opinion leaders to reflect recent progress in the field. It will be of great value to hematologists, oncologists, and allothers with an interest in Hodgkin lymphoma.

The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies.

This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health.

This book contains a series of contributions from internationally renowned academics with special expertise in one or other diseases which collectively are grouped under the heading myeloproliferative disorders. There have been many recent developments in understanding the pathophysiology and a number therapeutic innovations in this area. A feature of this book is the speed with which it has been produced - an important factor in this rapidly moving field.

This handbook provides up-to-date and comprehensive treatment of all plasma cell disorders, including both common and rare disorders. All disease aspects from pathogenesis to most recent therapy are covered. The text originates from the Mayo Clinic, the world's most experienced institution in plasma cell disorders. Comprehensive treatise on all plasma cell disorders from the gene level to treatment of emergencies Chapters are uniformly organized for easy data access All authors are important authorities in their field with extensive clinical experience

This book focuses on three of the main categories of myeloproliferative neoplasm: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Relevant laboratory and clinical advances are comprehensively covered, and great emphasis is placed on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic  approaches, the value and limitations of mutation screening for diagnostic and  prognostic purposes, risk stratification in terms of both survival and other  disease complications such as leukemic transformation and thrombosis, and  modern therapeutic strategies, including conventional drugs, allogeneic stem cell  transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.

The diagnosis of myelodysplastic syndromes (MDS), a heterogeneous group of clonal hematopoietic disorders, is being made with increasing frequency over the past decade owing to increased recognition, improved understanding, and an aging population. This book, completely updated since the first edition, summarizes in a concise and focused way the current knowledge of all aspects of MDS. Clinical presentation, etiology, epidemiology, molecular biology, classification, and staging are all discussed. Clear guidance is provided on diagnosis and differential diagnosis, and treatment strategies are explained in detail, including administration of hematopoietic growth factors, biologically based treatment, hematopoietic stem cell transplantation, and supportive care. Additional chapter is devoted to MDS in children. This practically oriented book will be of value to a broad spectrum of students and practitioners in the field.

After a decade of tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma, optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors.

Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. Thus, several chapters in this volume describe current knowledge of acute leukemia biology and discuss new classification systems that have arisen consequent to emerging insights into pathogenesis. Treatment has also improved for particular types of acute leukemia. Given our intention that the book be useful to clinicians, we pay particular attention to these advances, to management of acute leukemia in general, and to development of new therapies.

This book contains a series of contributions from internationally renowned academics with special expertise in one or other diseases which collectively are grouped under the heading myeloproliferative disorders. There have been many recent developments in understanding the pathophysiology and a number therapeutic innovations in this area. A feature of this book is the speed with which it has been produced - an important factor in this rapidly moving field.

After a decade of tremendous progress in the diagnostic and therapeutic approaches to malignant lymphoma, optimal treatment strategies are now based not only on accurate diagnosis but also on thorough evaluation of clinical and molecular risk factors. Even more importantly, molecular targeted approaches have been shown to be effective in the treatment of distinct lymphoma subtypes. Against this background, clinical management of especially the rare lymphomas remains a challenge for the general oncologist. This book provides a comprehensive overview of current treatment strategies in these rare lymphoma subtypes. Experts in the field from around the world describe histomorphology in a clinically relevant manner, consider the role of risk factors in detail, and discuss the spectrum of therapeutic approaches. Special emphasis is placed on the translation of molecular science into clinical care, and a disease-specific algorithm is proposed for each entity.

The diagnosis of myelodysplastic syndromes (MDS), a heterogeneous group of clonal hematopoietic disorders, is being made with increasing frequency over the past decade owing to increased recognition, improved understanding, and an aging population. This book, completely updated since the first edition, summarizes in a concise and focused way the current knowledge of all aspects of MDS. Clinical presentation, etiology, epidemiology, molecular biology, classification, and staging are all discussed. Clear guidance is provided on diagnosis and differential diagnosis, and treatment strategies are explained in detail, including administration of hematopoietic growth factors, biologically based treatment, hematopoietic stem cell transplantation, and supportive care. Additional chapter is devoted to MDS in children. This practically oriented book will be of value to a broad spectrum of students and practitioners in the field.